Global Migraine Market By Therapeutic Use (Acute, Preventive) By Therapeutic Class (CGRP monoclonal antibodies, CGRP small molecule antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs, Others) By Route of Administration (Oral, Injectable, Others) By Age Group (Pediatric, Adult, Geriatric) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Table of Contents

• 1. Executive Summary
  • 1.1. Definition
  • 1.2. Market Snapshot
  • 1.3. Market Overview
  • 1.4. Segment Overview
  • 1.5. Regional Overview
  • 1.6. Competitive Landscape
  • 1.7. Taxonomy
  • 1.8. Industry Voices
• 2. Global Market Overview
  • 2.1. Global Market Insights and Industry Overview
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunities
    • 2.2.4. Key Migraine Market Trends
  • 2.3. Therapeutic Class Landscape
  • 2.4. Regulatory Framework
  • 2.5. Sustainability and ESG (Environmental, Social, Governance)
  • 2.6. Opportunity Map Analysis
  • 2.7. Opportunity Orbits
  • 2.8. PESTLE Analysis
  • 2.9. PORTER’S Five Force Analysis
  • 2.10. Drivers & Restraints Impact Analysis
  • 2.11. Value Chain Analysis
    • 2.11.1. List of Raw Materials Suppliers
    • 2.11.2. List of Migraine Manufacturers
    • 2.11.3. List of Dealer/Distributors
  • 2.12. Regional Market Share and BPS Analysis
  • 2.13. Impact of Macro-economic Factors/Geopolitical Factors
• 3. Global Migraine Market Analysis and Forecast, By Segment, 2020-2034
  • 3.1. Key Findings
  • 3.2. Global Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Use, 2020-2034
  • 3.3. Global Migraine Market Attractiveness Analysis, By Therapeutic Use
    • 3.3.1. Acute
      • 3.3.1.1. Insights
      • 3.3.1.2. Key Takeaways
    • 3.3.2. Preventive
      • 3.3.2.1. Insights
      • 3.3.2.2. Key Takeaways
  • 3.4. Global Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Class, 2020-2034
  • 3.5. Global Migraine Market Attractiveness Analysis, By Therapeutic Class
    • 3.5.1. CGRP monoclonal antibodies
      • 3.5.1.1. Insights
      • 3.5.1.2. Key Takeaways
    • 3.5.2. CGRP small molecule antagonists
      • 3.5.2.1. Insights
      • 3.5.2.2. Key Takeaways
    • 3.5.3. Acetylcholine inhibitors/ neurotoxins
      • 3.5.3.1. Insights
      • 3.5.3.2. Key Takeaways
    • 3.5.4. Triptans
      • 3.5.4.1. Insights
      • 3.5.4.2. Key Takeaways
    • 3.5.5. Ditans
      • 3.5.5.1. Insights
      • 3.5.5.2. Key Takeaways
    • 3.5.6. Ergot alkaloids
      • 3.5.6.1. Insights
      • 3.5.6.2. Key Takeaways
    • 3.5.7. NSAIDs
      • 3.5.7.1. Insights
      • 3.5.7.2. Key Takeaways
    • 3.5.8. Others
      • 3.5.8.1. Insights
      • 3.5.8.2. Key Takeaways
  • 3.6. Global Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 3.7. Global Migraine Market Attractiveness Analysis, By Route of Administration
    • 3.7.1. Oral
      • 3.7.1.1. Insights
      • 3.7.1.2. Key Takeaways
    • 3.7.2. Injectable
      • 3.7.2.1. Insights
      • 3.7.2.2. Key Takeaways
    • 3.7.3. Others
      • 3.7.3.1. Insights
      • 3.7.3.2. Key Takeaways
  • 3.8. Global Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Age Group, 2020-2034
  • 3.9. Global Migraine Market Attractiveness Analysis, By Age Group
    • 3.9.1. Pediatric
      • 3.9.1.1. Insights
      • 3.9.1.2. Key Takeaways
    • 3.9.2. Adult
      • 3.9.2.1. Insights
      • 3.9.2.2. Key Takeaways
    • 3.9.3. Geriatric
      • 3.9.3.1. Insights
      • 3.9.3.2. Key Takeaways
  • 3.10. Global Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 3.11. Global Migraine Market Attractiveness Analysis, By Distribution Channel
    • 3.11.1. Hospital Pharmacies
      • 3.11.1.1. Insights
      • 3.11.1.2. Key Takeaways
    • 3.11.2. Retail Pharmacies
      • 3.11.2.1. Insights
      • 3.11.2.2. Key Takeaways
    • 3.11.3. Online Pharmacies
      • 3.11.3.1. Insights
      • 3.11.3.2. Key Takeaways
• 4. Global Migraine Market Analysis and Forecast, By Region, 2020-2034
  • 4.1. Key Findings
  • 4.2. Global Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
    • 4.2.1. North America
      • 4.2.1.1. Regional Insights
    • 4.2.2. Europe
      • 4.2.2.1. Regional Insights
    • 4.2.3. Asia Pacific
      • 4.2.3.1. Regional Insights
    • 4.2.4. Latin America
      • 4.2.4.1. Regional Insights
    • 4.2.5. Middle East & Africa
      • 4.2.5.1. Regional Insights
  • 4.3. Global Migraine Market Attractiveness Analysis, By Region
• 5. North America Migraine Market Analysis and Forecast, 2020-2034
  • 5.1. Key Findings
  • 5.2. North America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Use, 2020-2034
  • 5.3. North America Migraine Market Attractiveness Analysis, By Therapeutic Use
  • 5.4. North America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Class, 2020-2034
  • 5.5. North America Migraine Market Attractiveness Analysis, By Therapeutic Class
  • 5.6. North America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 5.7. North America Migraine Market Attractiveness Analysis, By Route of Administration
  • 5.8. North America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Age Group, 2020-2034
  • 5.9. North America Migraine Market Attractiveness Analysis, By Age Group
  • 5.10. North America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 5.11. North America Migraine Market Attractiveness Analysis, By Distribution Channel
  • 5.12. North America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 5.13. North America Migraine Market Attractiveness Analysis, By Country
    • 5.13.1. The US
    • 5.13.2. Canada
• 6. Europe Migraine Market Analysis and Forecast, 2020-2034
  • 6.1. Key Findings
  • 6.2. Europe Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Use, 2020-2034
  • 6.3. Europe Migraine Market Attractiveness Analysis, By Therapeutic Use
  • 6.4. Europe Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Class, 2020-2034
  • 6.5. Europe Migraine Market Attractiveness Analysis, By Therapeutic Class
  • 6.6. Europe Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 6.7. Europe Migraine Market Attractiveness Analysis, By Route of Administration
  • 6.8. Europe Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Age Group, 2020-2034
  • 6.9. Europe Migraine Market Attractiveness Analysis, By Age Group
  • 6.10. Europe Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 6.11. Europe Migraine Market Attractiveness Analysis, By Distribution Channel
  • 6.12. Europe Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 6.13. Europe Migraine Market Attractiveness Analysis, By Country
    • 6.13.1. Germany
    • 6.13.2. The UK
    • 6.13.3. France
    • 6.13.4. Spain
    • 6.13.5. Italy
    • 6.13.6. Russia
    • 6.13.7. Netherland
    • 6.13.8. Rest of Europe
• 7. Asia Pacific Migraine Market Analysis and Forecast, 2020-2034
  • 7.1. Key Findings
  • 7.2. Asia Pacific Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Use, 2020-2034
  • 7.3. Asia Pacific Migraine Market Attractiveness Analysis, By Therapeutic Use
  • 7.4. Asia Pacific Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Class, 2020-2034
  • 7.5. Asia Pacific Migraine Market Attractiveness Analysis, By Therapeutic Class
  • 7.6. Asia Pacific Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 7.7. Asia Pacific Migraine Market Attractiveness Analysis, By Route of Administration
  • 7.8. Asia Pacific Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Age Group, 2020-2034
  • 7.9. Asia Pacific Migraine Market Attractiveness Analysis, By Age Group
  • 7.10. Asia Pacific Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 7.11. Asia Pacific Migraine Market Attractiveness Analysis, By Distribution Channel
  • 7.12. Asia Pacific Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 7.13. Asia Pacific Migraine Market Attractiveness Analysis, By Country
    • 7.13.1. China
    • 7.13.2. Japan
    • 7.13.3. South Korea
    • 7.13.4. India
    • 7.13.5. Australia
    • 7.13.6. New Zealand
    • 7.13.7. Singapore
    • 7.13.8. Thailand
    • 7.13.9. Vietnam
    • 7.13.10. Rest of Asia Pacific
• 8. Latin America Migraine Market Analysis and Forecast, 2020-2034
  • 8.1. Key Findings
  • 8.2. Latin America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Use, 2020-2034
  • 8.3. Latin America Migraine Market Attractiveness Analysis, By Therapeutic Use
  • 8.4. Latin America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Class, 2020-2034
  • 8.5. Latin America Migraine Market Attractiveness Analysis, By Therapeutic Class
  • 8.6. Latin America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 8.7. Latin America Migraine Market Attractiveness Analysis, By Route of Administration
  • 8.8. Latin America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Age Group, 2020-2034
  • 8.9. Latin America Migraine Market Attractiveness Analysis, By Age Group
  • 8.10. Latin America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 8.11. Latin America Migraine Market Attractiveness Analysis, By Distribution Channel
  • 8.12. Latin America Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 8.13. Latin America Migraine Market Attractiveness Analysis, By Country
    • 8.13.1. Brazil
    • 8.13.2. Mexico
    • 8.13.3. Rest of Latin America
• 9. Middle East & Africa Migraine Market Analysis and Forecast, 2020-2034
  • 9.1. Key Findings
  • 9.2. Middle East & Africa Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Use, 2020-2034
  • 9.3. Middle East & Africa Migraine Market Attractiveness Analysis, By Therapeutic Use
  • 9.4. Middle East & Africa Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Therapeutic Class, 2020-2034
  • 9.5. Middle East & Africa Migraine Market Attractiveness Analysis, By Therapeutic Class
  • 9.6. Middle East & Africa Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 9.7. Middle East & Africa Migraine Market Attractiveness Analysis, By Route of Administration
  • 9.8. Middle East & Africa Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Age Group, 2020-2034
  • 9.9. Middle East & Africa Migraine Market Attractiveness Analysis, By Age Group
  • 9.10. Middle East & Africa Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 9.11. Middle East & Africa Migraine Market Attractiveness Analysis, By Distribution Channel
  • 9.12. Middle East & Africa Migraine Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 9.13. Middle East & Africa Migraine Market Attractiveness Analysis, By Country
    • 9.13.1. South Africa
    • 9.13.2. Saudi Arabia
    • 9.13.3. UAE
    • 9.13.4. Rest of Middle East & Africa
• 10. Competitive Landscape & Company Profiles
  • 10.1. Market Competition Scenario Analysis, By Company
    • 10.1.1. Key Takeaways
  • 10.2. Overview of Major Market Players
  • 10.3. Competitor Landscape
  • 10.4. Strategic Mapping
  • 10.5. Company Life Cycle Analysis
  • 10.6. Company Market Share Analysis
  • 10.7. Company Profiles
    • 10.7.1. Eli Lilly
      • 10.7.1.1. Company Details
      • 10.7.1.2. Business Overview
      • 10.7.1.3. Product Portfolio
      • 10.7.1.4. Financial Insights
      • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.1.6. SWOT Analysis
      • 10.7.1.7. Geographic Footprint
    • 10.7.2. Teva Pharmaceutical Industries
      • 10.7.2.1. Company Details
      • 10.7.2.2. Business Overview
      • 10.7.2.3. Product Portfolio
      • 10.7.2.4. Financial Insights
      • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.2.6. SWOT Analysis
      • 10.7.2.7. Geographic Footprint
    • 10.7.3. GlaxoSmithKline (GSK)
      • 10.7.3.1. Company Details
      • 10.7.3.2. Business Overview
      • 10.7.3.3. Product Portfolio
      • 10.7.3.4. Financial Insights
      • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.3.6. SWOT Analysis
      • 10.7.3.7. Geographic Footprint
    • 10.7.4. Pfizer
      • 10.7.4.1. Company Details
      • 10.7.4.2. Business Overview
      • 10.7.4.3. Product Portfolio
      • 10.7.4.4. Financial Insights
      • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.4.6. SWOT Analysis
      • 10.7.4.7. Geographic Footprint
    • 10.7.5. AbbVie
      • 10.7.5.1. Company Details
      • 10.7.5.2. Business Overview
      • 10.7.5.3. Product Portfolio
      • 10.7.5.4. Financial Insights
      • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.5.6. SWOT Analysis
      • 10.7.5.7. Geographic Footprint
    • 10.7.6. Allergan
      • 10.7.6.1. Company Details
      • 10.7.6.2. Business Overview
      • 10.7.6.3. Product Portfolio
      • 10.7.6.4. Financial Insights
      • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.6.6. SWOT Analysis
      • 10.7.6.7. Geographic Footprint
    • 10.7.7. Merck & Co.
      • 10.7.7.1. Company Details
      • 10.7.7.2. Business Overview
      • 10.7.7.3. Product Portfolio
      • 10.7.7.4. Financial Insights
      • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.7.6. SWOT Analysis
      • 10.7.7.7. Geographic Footprint
    • 10.7.8. Sanofi
      • 10.7.8.1. Company Details
      • 10.7.8.2. Business Overview
      • 10.7.8.3. Product Portfolio
      • 10.7.8.4. Financial Insights
      • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.8.6. SWOT Analysis
      • 10.7.8.7. Geographic Footprint
    • 10.7.9. Bausch Health
      • 10.7.9.1. Company Details
      • 10.7.9.2. Business Overview
      • 10.7.9.3. Product Portfolio
      • 10.7.9.4. Financial Insights
      • 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.9.6. SWOT Analysis
      • 10.7.9.7. Geographic Footprint
    • 10.7.10. Biohaven
      • 10.7.10.1. Company Details
      • 10.7.10.2. Business Overview
      • 10.7.10.3. Product Portfolio
      • 10.7.10.4. Financial Insights
      • 10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.10.6. SWOT Analysis
      • 10.7.10.7. Geographic Footprint
    • 10.7.11. Axsome Therapeutics
      • 10.7.11.1. Company Details
      • 10.7.11.2. Business Overview
      • 10.7.11.3. Product Portfolio
      • 10.7.11.4. Financial Insights
      • 10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.11.6. SWOT Analysis
      • 10.7.11.7. Geographic Footprint
    • 10.7.12. Theranica
      • 10.7.12.1. Company Details
      • 10.7.12.2. Business Overview
      • 10.7.12.3. Product Portfolio
      • 10.7.12.4. Financial Insights
      • 10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.12.6. SWOT Analysis
      • 10.7.12.7. Geographic Footprint
    • 10.7.13. Medtronic
      • 10.7.13.1. Company Details
      • 10.7.13.2. Business Overview
      • 10.7.13.3. Product Portfolio
      • 10.7.13.4. Financial Insights
      • 10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.13.6. SWOT Analysis
      • 10.7.13.7. Geographic Footprint
    • 10.7.14. eNeura
      • 10.7.14.1. Company Details
      • 10.7.14.2. Business Overview
      • 10.7.14.3. Product Portfolio
      • 10.7.14.4. Financial Insights
      • 10.7.14.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.14.6. SWOT Analysis
      • 10.7.14.7. Geographic Footprint
    • 10.7.15. Cefaly Technology
      • 10.7.15.1. Company Details
      • 10.7.15.2. Business Overview
      • 10.7.15.3. Product Portfolio
      • 10.7.15.4. Financial Insights
      • 10.7.15.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.15.6. SWOT Analysis
      • 10.7.15.7. Geographic Footprint
• 11. Methodology and Data Source
  • 11.1. Methodology/Research Approach
  • 11.2. Market Size Estimation
  • 11.3. Market Breakdown and Data Triangulation
  • 11.4. Data Source
  • 11.5. Secondary Sources
  • 11.6. Primary Sources
  • 11.7. Appendix
  • 11.8. Disclaimer

List of Tables

• Table 1. Global Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 2. Global Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 3. Global Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 4. Global Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 5. Global Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 6. Global Migraine Market Value (US$ Mn), By Region, 2020-2034
• Table 7. North America Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 8. North America Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 9. North America Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 10. North America Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 11. North America Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 12. North America Migraine Market Value (US$ Mn), By Country, 2020-2034
• Table 13. The US Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 14. The US Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 15. The US Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 16. The US Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 17. The US Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 18. Canada Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 19. Canada Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 20. Canada Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 21. Canada Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 22. Canada Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 23. Europe Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 24. Europe Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 25. Europe Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 26. Europe Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 27. Europe Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 28. Europe Migraine Market Value (US$ Mn), By Country, 2020-2034
• Table 29. Germany Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 30. Germany Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 31. Germany Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 32. Germany Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 33. Germany Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 34. The UK Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 35. The UK Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 36. The UK Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 37. The UK Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 38. The UK Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 39. France Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 40. France Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 41. France Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 42. France Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 43. France Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 44. Spain Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 45. Spain Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 46. Spain Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 47. Spain Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 48. Spain Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 49. Italy Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 50. Italy Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 51. Italy Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 52. Italy Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 53. Italy Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 54. Russia Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 55. Russia Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 56. Russia Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 57. Russia Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 58. Russia Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 59. Netherland Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 60. Netherland Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 61. Netherland Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 62. Netherland Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 63. Netherland Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 64. Rest of Europe Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 65. Rest of Europe Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 66. Rest of Europe Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 67. Rest of Europe Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 68. Rest of Europe Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 69. Asia Pacific Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 70. Asia Pacific Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 71. Asia Pacific Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 72. Asia Pacific Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 73. Asia Pacific Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 74. Asia Pacific Migraine Market Value (US$ Mn), By Country, 2020-2034
• Table 75. China Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 76. China Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 77. China Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 78. China Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 79. China Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 80. India Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 81. India Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 82. India Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 83. India Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 84. India Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 85. Japan Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 86. Japan Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 87. Japan Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 88. Japan Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 89. Japan Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 90. South Korea Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 91. South Korea Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 92. South Korea Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 93. South Korea Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 94. South Korea Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 95. Australia Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 96. Australia Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 97. Australia Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 98. Australia Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 99. Australia Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 100. New Zealand Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 101. New Zealand Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 102. New Zealand Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 103. New Zealand Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 104. New Zealand Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 105. Singapore Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 106. Singapore Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 107. Singapore Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 108. Singapore Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 109. Singapore Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 110. Thailand Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 111. Thailand Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 112. Thailand Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 113. Thailand Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 114. Thailand Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 115. Vietnam Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 116. Vietnam Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 117. Vietnam Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 118. Vietnam Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 119. Vietnam Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 120. Rest of Asia Pacific Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 121. Rest of Asia Pacific Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 122. Rest of Asia Pacific Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 123. Rest of Asia Pacific Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 124. Rest of Asia Pacific Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 125. Latin America Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 126. Latin America Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 127. Latin America Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 128. Latin America Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 129. Latin America Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 130. Latin America Migraine Market Value (US$ Mn), By Country, 2020-2034
• Table 131. Brazil Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 132. Brazil Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 133. Brazil Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 134. Brazil Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 135. Brazil Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 136. Mexico Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 137. Mexico Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 138. Mexico Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 139. Mexico Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 140. Mexico Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 141. Rest of Latin America Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 142. Rest of Latin America Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 143. Rest of Latin America Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 144. Rest of Latin America Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 145. Rest of Latin America Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 146. Middle East & Africa Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 147. Middle East & Africa Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 148. Middle East & Africa Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 149. Middle East & Africa Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 150. Middle East & Africa Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 151. Middle East & Africa Migraine Market Value (US$ Mn), By Country, 2020-2034
• Table 152. South Africa Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 153. South Africa Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 154. South Africa Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 155. South Africa Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 156. South Africa Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 157. Saudi Arabia Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 158. Saudi Arabia Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 159. Saudi Arabia Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 160. Saudi Arabia Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 161. Saudi Arabia Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 162. UAE Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 163. UAE Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 164. UAE Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 165. UAE Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 166. UAE Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 167. Rest of Middle East & Africa Migraine Market Value (US$ Mn), By Therapeutic Use, 2020-2034
• Table 168. Rest of Middle East & Africa Migraine Market Value (US$ Mn), By Therapeutic Class, 2020-2034
• Table 169. Rest of Middle East & Africa Migraine Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 170. Rest of Middle East & Africa Migraine Market Value (US$ Mn), By Age Group, 2020-2034
• Table 171. Rest of Middle East & Africa Migraine Market Value (US$ Mn), By Distribution Channel, 2020-2034

List of Figures

• Figure 1. Global Migraine Market Snapshot: Market Value (US$ Mn), 2020-2034
• Figure 2. Opportunity Map
• Figure 3. Opportunity Orbit
• Figure 4. Regional Market Share and BPS Analysis in Migraine Market
• Figure 5. Global Migraine Market Analysis, By Therapeutic Use, 2020, 2024 and 2034
• Figure 6. Global Migraine Market Attractiveness Analysis, By Therapeutic Use
• Figure 7. Global Migraine Market Analysis, By Therapeutic Class, 2020, 2024 and 2034
• Figure 8. Global Migraine Market Attractiveness Analysis, By Therapeutic Class
• Figure 9. Global Migraine Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 10. Global Migraine Market Attractiveness Analysis, By Route of Administration
• Figure 11. Global Migraine Market Analysis, By Age Group, 2020, 2024 and 2034
• Figure 12. Global Migraine Market Attractiveness Analysis, By Age Group
• Figure 13. Global Migraine Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 14. Global Migraine Market Attractiveness Analysis, By Distribution Channel
• Figure 15. Global Migraine Market Analysis, By Region, 2020, 2024 and 2034
• Figure 16. Global Migraine Market Attractiveness Analysis, By Region
• Figure 17. North America Migraine Market Analysis, By Therapeutic Use, 2020, 2024 and 2034
• Figure 18. North America Migraine Market Attractiveness Analysis, By Therapeutic Use
• Figure 19. North America Migraine Market (US$ Mn), by Acute, 2020-2034
• Figure 20. North America Migraine Market (US$ Mn), by Preventive, 2020-2034
• Figure 21. North America Migraine Market Analysis, By Therapeutic Class, 2020, 2024 and 2034
• Figure 22. North America Migraine Market Attractiveness Analysis, By Therapeutic Class
• Figure 23. North America Migraine Market (US$ Mn), by CGRP monoclonal antibodies, 2020-2034
• Figure 24. North America Migraine Market (US$ Mn), by CGRP small molecule antagonists, 2020-2034
• Figure 25. North America Migraine Market (US$ Mn), by Acetylcholine inhibitors/ neurotoxins, 2020-2034
• Figure 26. North America Migraine Market (US$ Mn), by Triptans, 2020-2034
• Figure 27. North America Migraine Market (US$ Mn), by Ditans, 2020-2034
• Figure 28. North America Migraine Market (US$ Mn), by Ergot alkaloids, 2020-2034
• Figure 29. North America Migraine Market (US$ Mn), by NSAIDs, 2020-2034
• Figure 30. North America Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 31. North America Migraine Market (US$ Mn), by Therapeutic Class 9, 2020-2034
• Figure 32. North America Migraine Market (US$ Mn), by CGRP monoclonal antibodies0, 2020-2034
• Figure 33. North America Migraine Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 34. North America Migraine Market Attractiveness Analysis, By Route of Administration
• Figure 35. North America Migraine Market (US$ Mn), by Oral, 2020-2034
• Figure 36. North America Migraine Market (US$ Mn), by Injectable, 2020-2034
• Figure 37. North America Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 38. North America Migraine Market Analysis, By Age Group, 2020, 2024 and 2034
• Figure 39. North America Migraine Market Attractiveness Analysis, By Age Group
• Figure 40. North America Migraine Market (US$ Mn), by Pediatric, 2020-2034
• Figure 41. North America Migraine Market (US$ Mn), by Adult, 2020-2034
• Figure 42. North America Migraine Market (US$ Mn), by Geriatric, 2020-2034
• Figure 43. North America Migraine Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 44. North America Migraine Market Attractiveness Analysis, By Distribution Channel
• Figure 45. North America Migraine Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 46. North America Migraine Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 47. North America Migraine Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 48. North America Migraine Market Analysis, By Country, 2020, 2024 and 2034
• Figure 49. North America Migraine Market Attractiveness Analysis, By Country
• Figure 50. Europe Migraine Market Analysis, By Therapeutic Use, 2020, 2024 and 2034
• Figure 51. Europe Migraine Market Attractiveness Analysis, By Therapeutic Use
• Figure 52. Europe Migraine Market (US$ Mn), by Acute, 2020-2034
• Figure 53. Europe Migraine Market (US$ Mn), by Preventive, 2020-2034
• Figure 54. Europe Migraine Market Analysis, By Therapeutic Class, 2020, 2024 and 2034
• Figure 55. Europe Migraine Market Attractiveness Analysis, By Therapeutic Class
• Figure 56. Europe Migraine Market (US$ Mn), by CGRP monoclonal antibodies, 2020-2034
• Figure 57. Europe Migraine Market (US$ Mn), by CGRP small molecule antagonists, 2020-2034
• Figure 58. Europe Migraine Market (US$ Mn), by Acetylcholine inhibitors/ neurotoxins, 2020-2034
• Figure 59. Europe Migraine Market (US$ Mn), by Triptans, 2020-2034
• Figure 60. Europe Migraine Market (US$ Mn), by Ditans, 2020-2034
• Figure 61. Europe Migraine Market (US$ Mn), by Ergot alkaloids, 2020-2034
• Figure 62. Europe Migraine Market (US$ Mn), by NSAIDs, 2020-2034
• Figure 63. Europe Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 64. Europe Migraine Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 65. Europe Migraine Market Attractiveness Analysis, By Route of Administration
• Figure 66. Europe Migraine Market (US$ Mn), by Oral, 2020-2034
• Figure 67. Europe Migraine Market (US$ Mn), by Injectable, 2020-2034
• Figure 68. Europe Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 69. Europe Migraine Market Analysis, By Age Group, 2020, 2024 and 2034
• Figure 70. Europe Migraine Market Attractiveness Analysis, By Age Group
• Figure 71. Europe Migraine Market (US$ Mn), by Pediatric, 2020-2034
• Figure 72. Europe Migraine Market (US$ Mn), by Adult, 2020-2034
• Figure 73. Europe Migraine Market (US$ Mn), by Geriatric, 2020-2034
• Figure 74. Europe Migraine Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 75. Europe Migraine Market Attractiveness Analysis, By Distribution Channel
• Figure 76. Europe Migraine Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 77. Europe Migraine Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 78. Europe Migraine Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 79. Europe Migraine Market Analysis, By Country, 2020, 2024 and 2034
• Figure 80. Europe Migraine Market Attractiveness Analysis, By Country
• Figure 81. Asia Pacific Migraine Market Analysis, By Therapeutic Use, 2020, 2024 and 2034
• Figure 82. Asia Pacific Migraine Market Attractiveness Analysis, By Therapeutic Use
• Figure 83. Asia Pacific Migraine Market (US$ Mn), by Acute, 2020-2034
• Figure 84. Asia Pacific Migraine Market (US$ Mn), by Preventive, 2020-2034
• Figure 85. Asia Pacific Migraine Market Analysis, By Therapeutic Class, 2020, 2024 and 2034
• Figure 86. Asia Pacific Migraine Market Attractiveness Analysis, By Therapeutic Class
• Figure 87. Asia Pacific Migraine Market (US$ Mn), by CGRP monoclonal antibodies, 2020-2034
• Figure 88. Asia Pacific Migraine Market (US$ Mn), by CGRP small molecule antagonists, 2020-2034
• Figure 89. Asia Pacific Migraine Market (US$ Mn), by Acetylcholine inhibitors/ neurotoxins, 2020-2034
• Figure 90. Asia Pacific Migraine Market (US$ Mn), by Triptans, 2020-2034
• Figure 91. Asia Pacific Migraine Market (US$ Mn), by Ditans, 2020-2034
• Figure 92. Asia Pacific Migraine Market (US$ Mn), by Ergot alkaloids, 2020-2034
• Figure 93. Asia Pacific Migraine Market (US$ Mn), by NSAIDs, 2020-2034
• Figure 94. Asia Pacific Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 95. Asia Pacific Migraine Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 96. Asia Pacific Migraine Market Attractiveness Analysis, By Route of Administration
• Figure 97. Asia Pacific Migraine Market (US$ Mn), by Oral, 2020-2034
• Figure 98. Asia Pacific Migraine Market (US$ Mn), by Injectable, 2020-2034
• Figure 99. Asia Pacific Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 100. Asia Pacific Migraine Market Analysis, By Age Group, 2020, 2024 and 2034
• Figure 101. Asia Pacific Migraine Market Attractiveness Analysis, By Age Group
• Figure 102. Asia Pacific Migraine Market (US$ Mn), by Pediatric, 2020-2034
• Figure 103. Asia Pacific Migraine Market (US$ Mn), by Adult, 2020-2034
• Figure 104. Asia Pacific Migraine Market (US$ Mn), by Geriatric, 2020-2034
• Figure 105. Asia Pacific Migraine Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 106. Asia Pacific Migraine Market Attractiveness Analysis, By Distribution Channel
• Figure 107. Asia Pacific Migraine Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 108. Asia Pacific Migraine Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 109. Asia Pacific Migraine Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 110. Asia Pacific Migraine Market Analysis, By Country, 2020, 2024 and 2034
• Figure 111. Asia Pacific Migraine Market Attractiveness Analysis, By Country
• Figure 112. Latin America Migraine Market Analysis, By Therapeutic Use, 2020, 2024 and 2034
• Figure 113. Latin America Migraine Market Attractiveness Analysis, By Therapeutic Use
• Figure 114. Latin America Migraine Market (US$ Mn), by Acute, 2020-2034
• Figure 115. Latin America Migraine Market (US$ Mn), by Preventive, 2020-2034
• Figure 116. Latin America Migraine Market Analysis, By Therapeutic Class, 2020, 2024 and 2034
• Figure 117. Latin America Migraine Market Attractiveness Analysis, By Therapeutic Class
• Figure 118. Latin America Migraine Market (US$ Mn), by CGRP monoclonal antibodies, 2020-2034
• Figure 119. Latin America Migraine Market (US$ Mn), by CGRP small molecule antagonists, 2020-2034
• Figure 120. Latin America Migraine Market (US$ Mn), by Acetylcholine inhibitors/ neurotoxins, 2020-2034
• Figure 121. Latin America Migraine Market (US$ Mn), by Triptans, 2020-2034
• Figure 122. Latin America Migraine Market (US$ Mn), by Ditans, 2020-2034
• Figure 123. Latin America Migraine Market (US$ Mn), by Ergot alkaloids, 2020-2034
• Figure 124. Latin America Migraine Market (US$ Mn), by NSAIDs, 2020-2034
• Figure 125. Latin America Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 126. Latin America Migraine Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 127. Latin America Migraine Market Attractiveness Analysis, By Route of Administration
• Figure 128. Latin America Migraine Market (US$ Mn), by Oral, 2020-2034
• Figure 129. Latin America Migraine Market (US$ Mn), by Injectable, 2020-2034
• Figure 130. Latin America Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 131. Latin America Migraine Market Analysis, By Age Group, 2020, 2024 and 2034
• Figure 132. Latin America Migraine Market Attractiveness Analysis, By Age Group
• Figure 133. Latin America Migraine Market (US$ Mn), by Pediatric, 2020-2034
• Figure 134. Latin America Migraine Market (US$ Mn), by Adult, 2020-2034
• Figure 135. Latin America Migraine Market (US$ Mn), by Geriatric, 2020-2034
• Figure 136. Latin America Migraine Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 137. Latin America Migraine Market Attractiveness Analysis, By Distribution Channel
• Figure 138. Latin America Migraine Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 139. Latin America Migraine Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 140. Latin America Migraine Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 141. Latin America Migraine Market Analysis, By Country, 2020, 2024 and 2034
• Figure 142. Latin America Migraine Market Attractiveness Analysis, By Country
• Figure 143. Middle East & Africa Migraine Market Analysis, By Therapeutic Use, 2020, 2024 and 2034
• Figure 144. Middle East & Africa Migraine Market Attractiveness Analysis, By Therapeutic Use
• Figure 145. Middle East & Africa Migraine Market (US$ Mn), by Acute, 2020-2034
• Figure 146. Middle East & Africa Migraine Market (US$ Mn), by Preventive, 2020-2034
• Figure 147. Middle East & Africa Migraine Market Analysis, By Therapeutic Class, 2020, 2024 and 2034
• Figure 148. Middle East & Africa Migraine Market Attractiveness Analysis, By Therapeutic Class
• Figure 149. Middle East & Africa Migraine Market (US$ Mn), by CGRP monoclonal antibodies, 2020-2034
• Figure 150. Middle East & Africa Migraine Market (US$ Mn), by CGRP small molecule antagonists, 2020-2034
• Figure 151. Middle East & Africa Migraine Market (US$ Mn), by Acetylcholine inhibitors/ neurotoxins, 2020-2034
• Figure 152. Middle East & Africa Migraine Market (US$ Mn), by Triptans, 2020-2034
• Figure 153. Middle East & Africa Migraine Market (US$ Mn), by Ditans, 2020-2034
• Figure 154. Middle East & Africa Migraine Market (US$ Mn), by Ergot alkaloids, 2020-2034
• Figure 155. Middle East & Africa Migraine Market (US$ Mn), by NSAIDs, 2020-2034
• Figure 156. Middle East & Africa Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 157. Middle East & Africa Migraine Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 158. Middle East & Africa Migraine Market Attractiveness Analysis, By Route of Administration
• Figure 159. Middle East & Africa Migraine Market (US$ Mn), by Oral, 2020-2034
• Figure 160. Middle East & Africa Migraine Market (US$ Mn), by Injectable, 2020-2034
• Figure 161. Middle East & Africa Migraine Market (US$ Mn), by Others, 2020-2034
• Figure 162. Middle East & Africa Migraine Market Analysis, By Age Group, 2020, 2024 and 2034
• Figure 163. Middle East & Africa Migraine Market Attractiveness Analysis, By Age Group
• Figure 164. Middle East & Africa Migraine Market (US$ Mn), by Pediatric, 2020-2034
• Figure 165. Middle East & Africa Migraine Market (US$ Mn), by Adult, 2020-2034
• Figure 166. Middle East & Africa Migraine Market (US$ Mn), by Geriatric, 2020-2034
• Figure 167. Middle East & Africa Migraine Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 168. Middle East & Africa Migraine Market Attractiveness Analysis, By Distribution Channel
• Figure 169. Middle East & Africa Migraine Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 170. Middle East & Africa Migraine Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 171. Middle East & Africa Migraine Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 172. Middle East & Africa Migraine Market Analysis, By Country, 2020, 2024 and 2034
• Figure 173. Middle East & Africa Migraine Market Attractiveness Analysis, By Country